Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Receives $36.60 Average Target Price from Analysts

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) has received an average recommendation of “Buy” from the five analysts that are presently covering the firm, MarketBeat.com reports. Five equities research analysts have rated the stock with a buy recommendation. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $36.60.

A number of brokerages have weighed in on KNSA. JPMorgan Chase & Co. raised their target price on shares of Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the company an “overweight” rating in a research report on Tuesday, November 5th. Jefferies Financial Group started coverage on Kiniksa Pharmaceuticals in a report on Friday, September 13th. They set a “buy” rating and a $40.00 price objective on the stock. Finally, Evercore ISI upped their target price on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th.

Kiniksa Pharmaceuticals Stock Performance

Kiniksa Pharmaceuticals stock opened at $22.08 on Wednesday. Kiniksa Pharmaceuticals has a 52 week low of $15.82 and a 52 week high of $28.15. The stock has a market capitalization of $1.59 billion, a P/E ratio of -157.71 and a beta of 0.35. The stock has a fifty day moving average of $23.95 and a 200-day moving average of $22.96.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its earnings results on Tuesday, October 29th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.17). Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The business had revenue of $112.21 million for the quarter, compared to analyst estimates of $111.51 million. During the same period in the previous year, the firm posted ($0.20) EPS. The firm’s revenue was up 67.4% compared to the same quarter last year. On average, research analysts forecast that Kiniksa Pharmaceuticals will post -0.55 earnings per share for the current year.

Insider Buying and Selling

In other Kiniksa Pharmaceuticals news, COO Eben Tessari sold 17,000 shares of the stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $26.87, for a total transaction of $456,790.00. Following the completion of the sale, the chief operating officer now owns 109,975 shares of the company’s stock, valued at approximately $2,955,028.25. This represents a 13.39 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider John F. Paolini sold 60,692 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $26.12, for a total transaction of $1,585,275.04. Following the completion of the transaction, the insider now owns 52,038 shares in the company, valued at $1,359,232.56. This trade represents a 53.84 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 95,192 shares of company stock valued at $2,479,390 over the last 90 days. 54.57% of the stock is owned by insiders.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. raised its position in shares of Kiniksa Pharmaceuticals by 0.6% in the 1st quarter. Vanguard Group Inc. now owns 2,981,894 shares of the company’s stock worth $58,833,000 after acquiring an additional 16,595 shares in the last quarter. Braidwell LP increased its holdings in Kiniksa Pharmaceuticals by 40.6% in the third quarter. Braidwell LP now owns 2,894,513 shares of the company’s stock worth $72,334,000 after purchasing an additional 836,210 shares in the last quarter. Rubric Capital Management LP lifted its stake in Kiniksa Pharmaceuticals by 10.2% in the second quarter. Rubric Capital Management LP now owns 2,419,103 shares of the company’s stock valued at $45,165,000 after buying an additional 223,094 shares during the period. Parkman Healthcare Partners LLC boosted its holdings in shares of Kiniksa Pharmaceuticals by 16.7% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 755,244 shares of the company’s stock worth $18,874,000 after buying an additional 108,102 shares in the last quarter. Finally, FMR LLC grew its position in shares of Kiniksa Pharmaceuticals by 36,925.0% during the 3rd quarter. FMR LLC now owns 696,810 shares of the company’s stock worth $17,413,000 after buying an additional 694,928 shares during the period. Institutional investors and hedge funds own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.